TrilliumBiO was proud to attend the Respiratory Innovation Summit in Orlando.

Aamir Ali, MD, Chief Medical Officer at TrilliumBiO, presented “Transforming Pulmonary Diagnostics Through Biomarker Innovation,” highlighting how novel biomarker approaches are reshaping disease detection and enabling earlier, more precise diagnosis.

We were honored to contribute to the ongoing dialogue on addressing unmet needs in pulmonary care and accelerating the path to better outcomes for patients.

TrilliumBiO was honored to attend the Rare Disease Summit in Philadelphia, where the rare disease community stood united in pursuit of advancing therapeutic innovation for areas of unmet medical need.

Robert Lavieri, PhD, VP, Business Development and Translation Medicine at TrilliumBiO, moderated the panel “Accelerating the Diagnostic Journey — Breaking Down Barriers to Rare Disease Identification”

Panelists included:

• Aamir Ali, MD, Chief Medical Officer, TrilliumBiO
• Alan Freeman, Esq., Chief Strategy Officer and General Counsel, Uncommon Cures
• David Mickle, Board of Directors, National PKU Alliance

TrilliumBiO was pleased to attend Annapolis Day 2026, the advocacy summit and leadership reception hosted by the Maryland Tech Council.

Kaustabh Basu, Associate Director, Business Development & Translational Medicine at TrilliumBiO, moderated the panel “Keeping Cures Within Reach: Maryland’s Path on Rare Disease.”

Panelists included:

• Alan Freeman, Esq., Chief Strategy Officer and General Counsel, Uncommon Cures
• Michael States, a rare disease advocate & patient